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Purpose 18 
To determine the frequency of patients suffering harm due to delay in 19 
ophthalmic care in the UK over a 12-month period. 20 
Methods 21 
Patients with deterioration in vision in at least one eye of 3 lines of Snellen 22 
acuity or 15 letters on ETDRS chart or deterioration in visual field deviation of 3 23 
decibels due to health service initiated delay in review or care were 24 
ascertained through the BOSU using prospective active surveillance involving 25 
all UK consultant ophthalmologists. Demographic details, diagnosis, cause and 26 
length of delay, and vision loss were then sought by questionnaire. 27 
Results 28 
238 cases reported between March 2015 and February 2016. 197/238 29 
questionnaires were returned (83%). 28 reports were out of the study period 30 
or did not meet the case definition. Median age was 76 years (range: 1 to 98 31 
years). Median delay was 22 weeks (range: 2 days to 5 ½ years). 72% 32 
experienced permanent reduction in visual acuity, 23% permanent 33 
deterioration in visual field. Main diagnoses were Glaucoma 42%, Age-related 34 
Macular Degeneration (AMD) 23% and Diabetic Retinopathy (DR) 16%. 18 35 
patients were eligible for Severely Sight Impaired (SSI) or Sight Impaired (SI) 36 
registration. Main causes were delayed follow-up (76%), lost referral (7%) and 37 
delayed treatment (8%). 38 
Conclusion 39 
Patients are suffering preventable harm due to health service initiated delay 40 
leading to permanently reduced vision. This is occurring in patients of all ages, 41 
but most consistently in those with chronic conditions. Delayed follow up or 42 
review is the cause in the majority of cases indicating a lack of capacity within 43 
the hospital eye service. 44 
 45 
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Introduction 50 
The NHS aspires to provide high-quality care that is safe, effective and focused 51 
on patient experience in pursuit of timely and compassionate care for every 52 
person who uses and relies on its services. This is, and always has been, 53 
determined by clinical need and free at the point of care (1). As part of this 54 
there are published guidelines detailing expected timescales for ophthalmic 55 
care and review which cover many common ophthalmic conditions. This 56 
includes a patient’s legal right to treatment within 18 weeks of referral (1). The 57 
NHS is committed through its constitution to providing a comprehensive 58 
service available to all that aspires to the highest standards of excellence and 59 
professionalism whilst putting the patient at the heart of every decision (1), 60 
however this does not include published NHS standards or commitment on the 61 
length of time for follow-up appointments. 62 
In 2009 the National Patient Safety Agency (NPSA) reported 44 glaucoma 63 
patients who experienced deterioration of vision, including 13 reports of total 64 
loss of vision, attributed to delayed follow up appointments over a 12-month 65 
period (2). They reported a further 91 incidents related to delayed, postponed 66 
or cancelled appointments for patients with glaucoma where the level of harm 67 
was not known. A more recent review by the National Reporting and Learning 68 
System (NRLS) of harm/ loss of vision, using the returns of the adverse event 69 
reporting system, identified nearly 500 incidences of harm – loss or 70 
deterioration of vision (27% severe harm and 73% moderate harm) in the 2 71 
year period between 2011 and 2013 (personal communication). 72 
These data were sourced through a generic cross specialty system and due to 73 
their free text nature, the reports contained no specified definition of severe 74 
or moderate and were unable to accurately determine the degree of sight loss, 75 
the associated eye conditions or the demographic characteristics of the 76 
affected patient population. However, they clearly describe the occurance of 77 
potentially unnecessary sight loss. This is a situation backed up by a growing 78 
number of reported concerns from ophthalmologists based upon clinical 79 
experience and news reports in the media (3). This study was undertaken to 80 
provide a robust estimate of the number of patients suffering serious harm 81 
due to delay in review or treatment, along with levels of recorded visual acuity 82 
or field loss, patient demographics, diagnosis, as well as the cause and length 83 
of the delay. 84 
 85 
Materials and methods 86 
Patients were identified prospectively using a system of nationwide active 87 
surveillance through the British Ophthalmological Surveillance Unit (BOSU) 88 
monthly reporting card system (4). All consultant or associate specialist 89 
ophthalmologists with clinical autonomy in the United Kingdom form the 90 
reporting base for the BOSU surveillance scheme. Each month they are sent a 91 
reporting card by BOSU requesting them to report if they have seen in the 92 
preceding month any patient with the conditions currently under surveillance. 93 
The BOSU then informs the respective study investigators which 94 
ophthalmologists have reported a case and the study investigators then 95 
contact the reporting ophthalmologist. 96 
For the 12-month study period between March 2015 and February 2016 97 
inclusive, ophthalmologists were asked to notify the study investigators, 98 
through the BOSU, of any of newly presenting patients who had sight loss due 99 
to delay in review or treatment. The definition of harm due to delay was 100 
defined as a deterioration of vision in at least one eye of 3 lines of Snellen 101 
acuity (or 15 letters on the ETDRS chart) or deterioration in the visual field of 3 102 
decibels or patients whose vision has deteriorated to below that measured on 103 
the Snellen Chart to Counting Fingers or worse due to a health service initiated 104 
delay in ophthalmic review or care. Delays caused by the patient’s failure to 105 
attend (DNA) were not included. 106 
Reporting ophthalmologists who notified the BOSU of a case were sent a 107 
questionnaire that sought information on the patients age, gender, ethnicity, 108 
diagnosis, cause and length of delay and deterioration in vision. 109 
Ophthalmologists who did not return the questionnaire were sent a reminder 110 
letter to increase the response rate. 111 
To improve the accuracy of the estimate of frequency, duplicate reports in the 112 
absence of any patient identifiers were recognised using probability matching 113 
of age, hospital, and date of appointment after delay. 114 
This study was given approval by the NHS Fife R&D department in January 115 
2015. 116 
Data were recorded in a Microsoft Access database. VA data were collected as 117 
recorded in the hospital notes, loss of vision was calculated using the raw data 118 
before being converted into lines on a Snellen chart equivalent. 119 
Results 120 
238 cases were reported to the BOSU during the 12 month study period and 121 
197/238 questionnaires were returned (response rate 83%). In total 28 case 122 
reports were subsequently excluded from the study (4 duplicate reports, 11 123 
did not meet the threshold for sight loss detailed in the case definition and 13 124 
referred to patients presenting before the study period). 169 confirmed cases 125 
meeting the case definition during the study period were identified. 126 
Patient demographics 127 
The median patient age was 76 years with a range of 1 year to 98 years. The 128 
distribution by life stage is shown in table 1. 129 
54% of the patients were male and 93.4% recorded their ethnicity as White, 130 
1.8% as Asian an 4.8% as Black. 131 
Diagnosis and visual loss 132 
The most frequent diagnoses were chronic conditions that required regular 133 
follow up (figure 1) 134 
There were incomplete visual data for 26 patients. For the 106 patients with a 135 
reported loss of acuity there was a median loss of the equivalent of 4 Snellen 136 
lines of acuity (range 1 to 9 lines) (table 2). Patients reported to have a loss of 137 
less than 3 lines either had an acuity of CF or worse or had associated field loss.  138 
Comparative visual field data were available for 46 patients. The median loss 139 
was 7 decibels with a range of 2 to 20, and 23 patients with a loss of greater 140 
than 8 decibels. 141 
132 patients experienced a permanent deterioration in vision. 98 had 142 
permanent loss of acuity, 28 had permanent deterioration in visual field, and 6 143 
had permanent deterioration in both acuity and visual fields. 13 patients were 144 
reported to have suffered a temporary loss of vision due to their delay in 145 
treatment or review but, of these, 9 required an unplanned surgical procedure. 146 
In addition, 6 patients with permanent deterioration in vision required an 147 
unplanned surgical intervention and 6 patients required to be admitted to 148 
hospital as an emergency. Twenty patients were reported to be eligible to be 149 
registered as severely sight impaired (blind) and 22 as sight impaired (partially 150 
sighted). 151 
Cause and length of delay 152 
The main cause of delay (80% of cases) was a follow-up appointment that 153 
occurred beyond the clinically recommended time. (figure 2).  154 
The median delay beyond the intended follow-up period was 22 weeks with a 155 
range of 2 days to 5 ½ years, with 26 patients experiencing a delay of over 12 156 
months. The proportionate delay as a multiple of planned follow-up (actual 157 
follow-up time/ planned follow-up time) is shown in figure 3. The median was 158 
2.8 times the planned follow-up time, with a range of 1.07 to 71 times. 159 
 160 
Discussion 161 
This study demonstrates, through nationwide prospective data collection, that 162 
patients who are within the hospital eye service are losing vision because of 163 
delays in their intended care. The main cause was a delayed follow-up 164 
appointment beyond the clinically recommended interval, which occurred in 165 
80% of affected patients. The majority of patients had chronic conditions 166 
requiring continuous long term follow-up, similar to that reported at 167 
Moorfields Eye Hospital (5) and this is likely to indicate an association between 168 
patient need and lack of health service capacity. The commonest reported 169 
diagnosis was glaucoma, a condition for which delayed follow up has 170 
previously been reported as a preventable cause of loss of vision (6,7). Within 171 
the context of an aging population, in which the estimated prevalence of 172 
glaucoma increases from 0.3% in the 40 – 50 year olds to 3.3% in those over 70 173 
(8), demand upon the health service to provide care continues to increase. 174 
At present, in contrast to appointments and treatment following initial (or 175 
new) referrals there are no targets or penalties imposed for hospitals that 176 
delay or re-book follow-up appointments to beyond the time interval 177 
recommended by the clinician. It is probable, and recognised by clinicians, that 178 
due to the requirements to meet the 18 week referral to treatment targets 179 
(RTT), hospitals are prioritising new referrals over reviews (7). This is despite 180 
review patients being significantly more likely to have confirmed pathology 181 
that may lead to vision loss and as demonstrated, delays for follow-up patients 182 
are resulting in this form of harm.  183 
The number of cases reported in this study represents the minimum frequency 184 
during the defined study period. Cases for this study were ascertained through 185 
a well-established surveillance methodology shown to be effective (9, 10) and 186 
to work in the UK healthcare context (4). However, it is probable that there is a 187 
degree of underascertainment. Previous reports for studies identifying cases 188 
through the BOSU have indicated that ascertainment rates usually lie between 189 
65% and 95%.(4,11).  190 
Although not directly linked to ascertainment, response rates are the most 191 
common method for assessing underascertainment (9). Higher response rates 192 
do correlate with better overall ascertainment (12), which means that the 193 
BOSU card return rate of 76% and the questionnaire return rate of 83% during 194 
the study period indicate high levels of compliance. This suggests that this 195 
study’s ascertainment was in line with other previous BOSU studies. Adjusting 196 
for underascertainment would provide a potential likely frequency of between 197 
178 and 260 cases per year (between 15 and 22 cases per month in the UK). 198 
The BOSU reporting scheme is dependent on voluntary reporting and there is 199 
evidence of good compliance from reporting ophthalmologists. However, the 200 
effects of systematic under-reporting should be considered, for example where 201 
reporting cases may have been perceived to affect the reputation and future 202 
care provision within an organisation, despite the investigators clearly stating 203 
that all data would be amalgamated before being published.  204 
The NRLS estimated approximately 250 cases of harm due to delay per year 205 
(personal communication). This is a similar figure to one we report; however, it 206 
should be noted that their estimates were based upon adverse event reporting 207 
and there were no predetermined definitions of harm beyond the reporters’ 208 
own perception of the terms moderate and severe. We have ensured that 209 
those patients reported had suffered significant deterioration of vision beyond 210 
any level that might be an artefact of measurement or that which would be 211 
expected were standard care provided. We have therefore identified a genuine 212 
source of otherwise preventable iatrogenic sight loss. This study did not 213 
attempt to measure the less explicit levels of harm. However, Davies identified 214 
16 cases of harm occurring in 12 316 lost to follow-up clinical reviews (8). This 215 
further suggests that those identified in this study are drawn from a much 216 
larger population of patients being placed at risk of significant harm or 217 
unfavourable prognosis due to health service initiated delays. 218 
In this study 42 patients were reported to have become eligible for sight 219 
impairment (partial sight) or severe sight impairment (blind) registration 220 
following a delay in review or treatment. Previous models of costs and 221 
outcomes have illustrated the financial benefit of preventing vision loss and 222 
blindness which is estimated to amount to £28 billion per year in the UK (13). 223 
However, patients are suffering preventable harm due to health service 224 
initiated delays and this is leading to permanently reduced vision – a problem 225 
that has been recognised for nearly 15 years. Whilst this is occurring in patients 226 
of all ages, it is most consistent in those with chronic conditions associated 227 
with aging. In common with previous reports, we have been able to identify 228 
that delayed follow up appointments are the cause in the vast majority of 229 
cases indicating a lack of capacity. The data from this study are limited to a 230 
cross-sectional description but reaffirms the need for consistent robust 231 
surveillance systems to monitor patients and the subsequent potential health 232 
benefits to provide information on trends. (5,6) 233 
It is recognised that loss of vision impacts negatively on both physical and 234 
mental health – those with sight loss are more likely to suffer falls (14), 235 
depression(15) and to become dependent on social services at an earlier stage.  236 
For children poor vision may lead to a lifetime of difficulty in reaching full 237 
potential as well as educational and developmental challenges. For those in 238 
the working age group, poor vision commonly precludes meaningful 239 
employment (16). It is extremely concerning that patients who are within the 240 
hospital system are losing vision because they are not receiving the care they 241 
need in a timely fashion. 242 
The solutions lie in making collection and reporting of the intended follow up 243 
date of outpatient appointments compulsory, optimising capacity in 244 
ophthalmic out-patient departments and empowering patients to challenge 245 
delays (17). 246 
The collection of data on the difference between the actual and intended 247 
appointment date will highlight individual patient delays and measure the 248 
shortfall in overall capacity across, not just ophthalmology, but all specialties to 249 
identify capacity deficits and where resources, systems and patient care could 250 
be improved. This would also improve individual patient safety as alerts to 251 
unsafe delays would be evident. 252 
 253 
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